STOCK TITAN

Sellas Life Sciences Group Inc SEC Filings

SLS NASDAQ

Welcome to our dedicated page for Sellas Life Sciences Group SEC filings (Ticker: SLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

SELLAS Life Sciences’ oncology pipeline is exciting—but its SEC paperwork can feel like a clinical protocol. Each annual report dissects Phase 3 GPS immunotherapy data, while 8-K material events flag trial pauses, licensing milestones, or new ATM financings. Tracking those disclosures—and the executive stock transactions Form 4 that sometimes precede them—takes time most investors don’t have.

That’s why Stock Titan brings every SELLAS Life Sciences quarterly earnings report 10-Q filing, insider trading Form 4 transactions and proxy statement executive compensation section into one AI-powered view. Our engine converts technical language into plain English, so understanding SELLAS Life Sciences SEC documents with AI becomes as direct as reading a headline. Need the latest SELLAS Life Sciences Form 4 insider transactions real-time? You’ll see alerts within minutes of EDGAR posting. Curious how cash burn compares Q-over-Q? The platform highlights the numbers for you, then links straight to the audited footnote.

  • Instant summaries that make the SELLAS Life Sciences annual report 10-K simplified—focus on drug-development timelines, dilution risks and collaboration revenue.
  • Auto-tagged sections so you can jump to “research & development expense” or “ASXL1 biomarker data” without scrolling 200 pages.
  • Side-by-side analysis of every SELLAS Life Sciences earnings report filing analysis for trend spotting.
  • One-click access to SELLAS Life Sciences 8-K material events explained, from FDA designations to financing agreements.

Whether you want SELLAS Life Sciences insider trading Form 4 transactions before the next 8-K, or just a clear view of how GPS milestones impact valuation, our real-time feed and concise AI commentary turn dense disclosures into actionable insight—no biotech PhD required.

Rhea-AI Summary

The Form 8-K filed by SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) discloses the voting results from the Company’s Annual Meeting held on June 17, 2025. Of the 94.5 million shares outstanding, 61.3 million (64.85%) were present or represented by proxy.

  • Board elections: Class III directors Angelos M. Stergiou and John Varian were re-elected, receiving 83% and 84% of votes cast, respectively, excluding broker non-votes.
  • Auditor ratification: Stockholders confirmed Baker Tilly US, LLP as independent auditor for FY 2025 with a strong 86.9% “For” vote.
  • Equity plan amendment: An increase of 800,000 shares under the 2021 Employee Stock Purchase Plan was approved (66% “For”).
  • Say-on-pay: The advisory resolution on executive compensation passed with 69% support.
  • Say-on-frequency: A plurality of holders (74%) preferred an annual vote on executive compensation.
  • Adjournment authority: Shareholders granted the Board discretion to adjourn the meeting if additional proxy solicitation were needed.

No other matters were presented, and no financial performance data or strategic transactions were reported in this filing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report

FAQ

What is the current stock price of Sellas Life Sciences Group (SLS)?

The current stock price of Sellas Life Sciences Group (SLS) is $1.84 as of July 11, 2025.

What is the market cap of Sellas Life Sciences Group (SLS)?

The market cap of Sellas Life Sciences Group (SLS) is approximately 216.5M.

What is the primary focus of SELLAS Life Sciences Group Inc?

SELLAS is focused on the development of novel therapeutics for a broad range of cancer indications, primarily through innovative immunotherapies and targeted small molecule inhibitors.

What are the lead product candidates of SELLAS?

The company’s leading products include galinpepimut-S (GPS), a peptide immunotherapy targeting WT1, and SLS009, a selective CDK9 inhibitor designed to treat multiple cancer types, including AML and various lymphomas.

How does SELLAS differentiate itself in the competitive oncology market?

SELLAS differentiates itself by integrating advanced biomarker research, conducting rigorous clinical trials, and forming strategic collaborations with academic institutions and leading healthcare centers to advance precise, targeted cancer therapies.

What clinical trials are currently underway at SELLAS?

SELLAS is running a Phase 3 trial (REGAL study) of GPS in AML patients and various Phase 2 trials for SLS009, exploring its efficacy in combination regimens and targeting specific genetic markers such as ASXL1 mutations.

What regulatory recognitions has SELLAS achieved?

The company has secured important regulatory designations such as Orphan Drug and Rare Pediatric Disease Designations from agencies like the FDA and EMA, validating its approach to addressing diseases with critical unmet needs.

How does SELLAS use biomarkers in its therapeutic development?

SELLAS incorporates biomarker research, particularly the study of ASXL1 mutations, to better predict patient responses and tailor clinical trials, aligning with the goals of precision medicine.

What is the significance of their partnership with leading research institutions?

Collaborations with institutions such as Memorial Sloan Kettering Cancer Center enhance the company’s scientific credibility and provide access to cutting-edge research, which is integral to the development of their innovative therapies.

How does SELLAS ensure patient safety and treatment efficacy in its clinical studies?

The company employs rigorous clinical protocols with oversight from independent data monitoring committees, ensuring that safety and efficacy are thoroughly evaluated and transparently reported throughout the trial phases.
Sellas Life Sciences Group Inc

NASDAQ:SLS

SLS Rankings

SLS Stock Data

216.52M
99.44M
0.17%
8.54%
9.93%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW YORK